Overview
The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.
Description
This study was a single-center retrospective clinical study, which retrospectively collected the clinical data of all eligible patients receiving chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgical treatment in Henan Tumor Hospital from June 1, 2012 to May 30, 2022. The efficacy, recurrence and survival of various treatments were collected.
Eligibility
Inclusion Criteria:
No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in
our hospital. Has received at least one hospitalization in this hospital. Target lesions
can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version
1.1) Measure diameter changes.
Complete follow-up data.
Exclusion Criteria:
No clear pathology. Incomplete follow-up data.